TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$85 Million

Sutro Biopharma

Initial Public Offering

Lead Left Bookrunner, August 2018

Sutro Biopharma
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders. The company aims to design therapeutics using the most potent modalities, including cytokine-based immuno-oncology, or I/O, therapeutics, antibody-drug conjugates, or ADCs, and bispecific antibodies that are directed primarily against clinically validated targets where the current standard of care is suboptimal. Sutro believes its platform accelerates the discovery and development of potential first-in-class and best-in-class molecules by enabling the rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.